Integrating biomarker-derived individual treatment response assessment into Bayesian trial design for personalized cancer treatment

Key Points

• Evaluate the integration of biomarker-derived treatment response assessments into Bayesian trial designs for cancer therapy.
• Utilized Bayesian trial design for incorporating biomarkers into treatment plans.
• Conducted simulations to identify intermediate responders for dose escalation.
• Compared biomarker stratification efficacy with conventional trial designs.
• Identified intermediate responders as optimal for dose escalation.
• Poor and strong responders demonstrated limited benefits due to increased toxicity risks.
• Stratification was feasible with about 100 patients, showing advantages over traditional methods.